Investor Relations
Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders. We commercialize a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets.
Our prescription WatchPAT family of products, which utilizes the PAT signal, is designed to enable patients suspected to have sleep related breathing disorders to easily conduct sleep apnea tests in the comfort of their homes in accordance with a physician’s instructions, as authorized by qualified medical personnel while delivering the treating physicians with comprehensive, accurate and reliable results to aid in the diagnosis of sleep apnea.
CAESAREA, Israel, May 05, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results
Significant Majority Expect Home Sleep Apnea Test Usage to Expand and in-lab Usage to Decline Most Clinicians Expect More than Half of Future Sleep Diagnostics W ill B e At-Home Tests Results Indicate Vast Majority of Participants Use HSAT in Their Practices Today CAESAREA, Israel, April 12, 2021
- Record Fourth Quarter 2020 Revenues Increase 31% to $ 12.8 Million - - U.S. WatchPAT™ Revenues Increase 39 % to $ 10.2 Million - - Full Year 2021 Revenue Guidance of $ 52 Million and $ 53 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, March 02,
CAESAREA, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results
A survey commissioned by Itamar Medical found that a third of respondents were unaware that treating sleep apnea can significantly reduce the health risks associated with cardiovascular disease, diabetes, and stroke ATLANTA, Feb. 16, 2021 (GLOBE NEWSWIRE) -- According to a survey commissioned by
CAESAREA, Israel, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the company will
May 19, 2021 at 8:00 AM EDT
Mar 4, 2021 at 10:30 AM EST
Mar 2, 2021 at 8:00 AM EST
Feb 25, 2021 at 8:00 AM EST
